January 24, 2020 07:09 AM ESTUpdated January 24, 07:53 PM
Pharma
FDA+

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

Amber Tong

Af­ter win­ning the hearts of the ex­pert pan­el con­vened by the FDA de­spite a bleak in-house re­view and a check­ered de­vel­op­ment his­to­ry, Robert Baze­more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times